Ischaemic Stroke
Ischaemic stroke occurs when a blood clot blocks blood flow to the brain, leading to brain cell damage. It can cause sudden symptoms like weakness, difficulty speaking, and loss of coordination.
Acute Ischemic Stroke: Redasemtide Study
We are investigating whether redasemtide can improve recovery in adults who have had an acute ischemic stroke. Participants will receive either the medication or a placebo to compare effects.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Are you currently pregnant or breastfeeding?
- Do you have a history of stroke or a current transient ischemic attack?
- Are you taking any medications that could interfere with the study, such as blood thinners like Warfarin, Eliquis, or Xarelto?
- Is your blood pressure currently below 220/120 mm Hg after treatment?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
S-005151
Redasemtide
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
UZ Brussel
Ganshoren, Belgium
UZ Leuven
Clinical and Experimental Neurology
Heverlee, Belgium
Universitair Ziekenhuis Gent
Neurology
Ledeberg, Belgium
Sponsor: Shionogi B.V.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.